Package Leaflet: Information for the Patient
Latanoprost Stadafarma 50 micrograms/ml eye drops, solution in single-dose container
Read this entire leaflet carefully before you start using this medicine, because it contains important information for you.
Contents of the package leaflet
Latanoprost Stadafarma belongs to a group of medicines known as prostaglandin analogues. It works by increasing the natural outflow of fluid from the inside of the eye into the bloodstream.
Latanoprost Stadafarma is used to treat conditions known as open-angle glaucomaand ocular hypertension. Both of these conditions are related to an increase in pressure within the eye, which can lead to problems with your sight.
Do not useLatanoprost Stadafarma
Warnings and precautions
If you think any of the following apply to you, talk to your doctor or pharmacist before you start using latanoprost:
Children
This medicine has not been studied in children (under 18 years of age).
Other medicines and Latanoprost Stadafarma
Latanoprost may interact with other medicines. Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Pregnancy and breastfeeding
Do not uselatanoprost if you are pregnant or breastfeeding, unless your doctor considers it necessary.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Driving and using machines
When using latanoprost, you may experience blurred vision for a short time. If this happens, do not driveor use tools or machines until your vision is clear again.
Latanoprost Stadafarma contains phosphates
This medicine contains 6.3 mg/ml of phosphates, which is equivalent to 0.24 mg/drop.
If you have severe damage to the clear layer on the front of your eye (the cornea), treatment with phosphates, in very rare cases, may cause cloudy patches on the cornea due to calcium deposits formed during treatment.
Contact lens wearers
If you wear contact lenses, you should remove them before using latanoprost. After applying latanoprost, wait 15 minutes before putting your contact lenses back in.
Instructions for use
Each carton contains 3 or 9 bags. Open only 1 bag at a time. Use all the single-dose containers before opening a new bag.
Separate the single-dose container from the strip before use.
If you use Latanoprost Stadafarma with other eye drops
Wait at least 5 minutes between the application of latanoprost and the administration of other eye drops.
If you use more Latanoprost Stadafarma than you should
If you have applied more drops in the eye than you should, you may feel a slight irritation in the eye and your eyes may become red and watery. This should pass, but if you are concerned, contact your doctor.
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicological Information Service, phone 91 562 04 20, indicating the medicine and the amount used.
If you forget to use Latanoprost Stadafarma
Continue with the next dose as usual. Do not apply an extra drop in the eye to make up for the missed dose. If you have any doubts, consult your doctor or pharmacist.
If you stop using Latanoprost Stadafarma
If you want to stop using latanoprost, consult your doctor.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following are known side effects of this medicine:
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
In very rare cases, some patients with severe damage to the clear layer on the front of the eye (cornea) have developed cloudy patches on the cornea due to calcium deposits formed during treatment.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Monitoring System for Human Use. https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, on the bag, and on the single-dose container. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Keep the bag in the carton after opening to protect from light.
After first opening of the bag: use the single-dose containers within 20 days.
After first opening of the single-dose container: use immediately and discard the single-dose container after use.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Latanoprost Stadafarma
Appearance of the product and contents of the pack
Latanoprost Stadafarma 50 micrograms/ml eye drops is a colorless or pale yellow solution in a single-dose container.
The single-dose containers are packaged in bags of 10 units (2 strips of 5 single-dose containers), each single-dose container contains 0.2 ml of solution.
The cartons contain 30 single-dose containers (3 bags with 10 single-dose containers) or 90 single-dose containers (9 bags with 10 single-dose containers).
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
Pharma Stulln GmbH
Werksstrasse 3
92551 Stulln, Germany
This medicine is authorised in the Member States of the European Economic Area under the following names:
Germany Latanoprost AL 50 Mikrogramm/ml Augentropfen, Lösung im Einzeldosisbehältnis
Date of last revision of this leaflet:May 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)